Home Momenta Pharmaceuticals Announces Publication Revealing Development Of A Novel Process To Generate High-Quality Hyper-Sialylated IVIg Drug Candidate In PNAS
 

Keywords :   


Momenta Pharmaceuticals Announces Publication Revealing Development Of A Novel Process To Generate High-Quality Hyper-Sialylated IVIg Drug Candidate In PNAS

2015-03-04 05:59:44| drugdiscoveryonline Home Page

Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that results from preclinical studies on its hyper-sialylated IVIg (hsIVIg) program were published in this week's Early Edition of Proceedings of the National Academy of Sciences (PNAS)

Tags: development process publication drug

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
26.11Trump proves he is serious on tariffs - but it's not about trade
26.11L
26.11 2019 BBM10
26.11Disney/Pixar Spooky Night
26.11 33
26.1114
26.11[272] ELMA03
26.113D
More »